



COMPANY INSPECTED BY CERTIQUALITY
FOR THE COMPLIANCE TO
GMP
CODE OF FEDERAL REGULATION,
TITLE 21, VOLUME 2, PART 111



LABOMAR, ON OCTOBER 19 AND 20 THE FIRST 'INVESTOR DAY '

Istrana, October 19th, 2021 – Labomar S.p.A., a company listed on the AIM market of the Italian Stock Exchange, will hold the **first Investor Day on Tuesday 19 and Wednesday 20 October** at the **company's headquarters in Istrana (Treviso)**.

Dedicated to Italian and foreign investors, the Investor Day includes a **visit to the production and R&D department of Labomar** (in two shifts, on October 19 in the afternoon and on October 20 in the morning), a management presentation in the afternoon of October 19, followed by a dinner which will also be attended by the management of the company.

The Investor Day will be an opportunity for investors to learn more about Labomar, its history and business model, as well as meeting the founder and President, Walter Bertin, and the other managers of the company.

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is a CDMO (Contract Development and Manufacturing Organization) engaged in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Its research team creates, develops and manufactures high added-value and innovative content nutraceutical products. Many of the supplements produced by Labomar leverage proprietary technologies which boost the bioavailability of the active ingredients, modulate their gastrointestinal absorption and improve their taste. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a high quality and productivity standard full service. The company boasts a well-structured and cutting-edge research and development department, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2020 preliminary consolidated revenues of approx. Euro 61.1 million (at like-for-like exchange rates approx. Euro 61.5 million), up 26.3% (27.2% at like-for-like exchange rates) on 2019. The 2020 figure includes - for the first time - the revenues and margins of the Canadian ImportFab for a full year, acquired in October 2019. Labomar SpA's revenues in 2020 were approx. Euro 51.8 million (+10.2% vs 2019).

In July 2021, Labomar acquired 63% of the Welcare Group. The Group comprises Welcare Industries S.p.A. and Welcare Research S.r.l., producers of medical devices for skincare, with its registered office in Orvieto.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For Information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it



COMPANY INSPECTED BY CERTIQUALITY
FOR THE COMPLIANCE TO
GMP
CODE OF FEDERAL REGULATION,
TITLE 21, VOLUME 2, PART 111



LABOMAR

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39.335.7737417 - mara@twin.services

NOMAD

Banca Mediolanum +39.02.9049 2525 - ecm@mediolanum.it